1
|
Apolone G, Ardizzoni A, Biondi A, Bortolami A, Cardone C, Ciniselli CM, Conte P, Crippa C, de Braud F, Duca M, Gori S, Gritti G, Inno A, Luksch R, Lussana F, Maio M, Pasello G, Perrone F, Rambaldi A, Rossi G, Signorelli D, Soverini G, Valente M, Verderio P, Buzzetti G. Skip pattern approach toward the early access of innovative anticancer drugs. ESMO Open 2021; 6:100227. [PMID: 34352703 PMCID: PMC8350180 DOI: 10.1016/j.esmoop.2021.100227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 06/29/2021] [Accepted: 07/06/2021] [Indexed: 10/29/2022] Open
Abstract
BACKGROUND With the rapid development of innovative anticancer treatments, the optimization of tools able to accelerate the access of new drugs to the market by the regulatory authority is a major issue. The aim of the project was to propose a reliable methodological pathway for the assessment of clinical value of new therapeutic innovative options, to objectively identify drugs which deserve early access (EA) priority for solid and possibly in other cancer scenarios, such as the hematological ones. MATERIALS AND METHODS After a comprehensive review of the European Public Assessment Report of 21 drugs, to which innovation had previously been attributed by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), an expert panel formulated an algorithm for the balanced use of three parameters: Unmet Medical Need (UMN) according to AIFA criteria, Added Benefit (AB) according to the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (ESMO-MCBS) criteria and Quality of Evidence (QE) assessed by the Grades of Recommendation Assessment, Development and Evaluation (GRADE) method. By sequentially combining the above indicators, a final priority status (i.e. EA or not) was obtained using the skip pattern approach (SPA). RESULTS By applying the SPA to the non-curative setting in solid cancers, the EA status was obtained by 5 out of 14 investigated drugs (36%); by enhancing the role of some categories of the UMN, additional 4 drugs, for a total of 9 (64%), reached the EA status: 2 and 3 drugs were excluded for not achieving an adequate score according to AB and QE criteria, respectively. For hematology cancer, only the UMN criteria were found to be adequate. CONCLUSIONS The use of this model may represent a reliable tool for assessment available to the various stakeholders involved in the EA process and may help regulatory agencies in a more comprehensive and objective definition of new treatments' value in these contexts. Its generalizability in other national contexts needs further evaluation.
Collapse
Affiliation(s)
- G Apolone
- Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Ardizzoni
- Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy
| | - A Biondi
- Department of Pediatrics, University of Milano Bicocca-Fondazione MBBM/Ospedale San Gerardo, Monza, Italy
| | - A Bortolami
- Rete Oncologica Veneta, Istituto Oncologico Veneto, Padova, Italy
| | - C Cardone
- Experimental Clinical Abdominal Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy
| | - C M Ciniselli
- Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - P Conte
- Istituto Oncologico Veneto, Padova, Italy
| | - C Crippa
- Department of Hemathology, Spedali Civili di Brescia, Brescia, Italy
| | - F de Braud
- Department of Medical Oncology & Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Duca
- Department of Medical Oncology & Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - S Gori
- Department of Oncology, IRCCS Sacro Cuore Don Calabria Hospital of Negrar, Verona, Italy
| | - G Gritti
- Hematology and Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - A Inno
- Department of Oncology, IRCCS Sacro Cuore Don Calabria Hospital of Negrar, Verona, Italy
| | - R Luksch
- Department of Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - F Lussana
- Hematology and Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - M Maio
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy
| | - G Pasello
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy
| | - F Perrone
- Clinical Trials Unit, National Cancer Institute of Naples, Napoli, Italy
| | - A Rambaldi
- Department of Oncology-Hematology, University of Milan, Milano, Italy; Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - G Rossi
- Deparment of Hematology ASST Spedali Civili di Brescia, Brescia, Italy
| | - D Signorelli
- Department of Medical Oncology & Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Niguarda Cancer Center-Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - G Soverini
- Deparment of Hematology ASST Spedali Civili di Brescia, Brescia, Italy
| | - M Valente
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy
| | - P Verderio
- Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
| | | |
Collapse
|
2
|
Gallamini A, Rambaldi A, Patti C, Romano A, Viviani S, Bolis S, Oppi S, Trentin L, Cantonetti M, Sorasio R, Gavarotti P, Gottardi D, Schiavotto C, Battistini R, Gini G, Ferreri A, Pavoni C, Bergesio F, Ficola U, Guerra L, Chauvie S. BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.19_2879] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A Gallamini
- Antoine Lacassagne Cancer Center Research and Clinical Innovation Nice France
| | - A Rambaldi
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - C Patti
- Ospedali Riuniti di Palermo Hematology Palermo Italy
| | - A Romano
- Policlinico Universitario A. Ferrarotto Hematology Catania Italy
| | - S Viviani
- Istituto Europeo di Ematologia Hematology Milano Italy
| | - S Bolis
- Ospedale S. Gerardo Hematology Monza Italy
| | - S Oppi
- Ospedale Antonio Businco Hematology Cagliari Italy
| | - L Trentin
- Azienda Ospedaliera di Padova Hematology Padova Italy
| | | | - R Sorasio
- Ospedale S. Croce e Carle Hematology Cuneo Italy
| | - P Gavarotti
- Ospedale S. Giovanni Battista Hematology ‐ University Torino Italy
| | - D Gottardi
- Ospedale Mauriziano Hematology Torino Italy
| | | | - R Battistini
- Ospedale S. Camillo Forlanini Hematology Roma Italy
| | - G Gini
- Ospedali Riuniti di Ancona Hematology Ancona Italy
| | | | - C Pavoni
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - F Bergesio
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| | - U Ficola
- Ospedale La Maddalena Nuclear Medicine Palermo Italy
| | - L Guerra
- Ospedale S. Gerardo Nuclear Medicine Monza Italy
| | - S Chauvie
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| |
Collapse
|
3
|
Gallamini A, Walewski J, Rambaldi A, Viviani S, Sureda A, André M, Rossi C, Moccia A, Zucca E, Rossi D, Filippi A, Meignan M, Chauvie S, Zaucha JM. RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.158_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Gallamini
- Antoine Lacassagne Cancer Center Research and Clinical Innovation Nice France
| | - J. Walewski
- Marii Skłodowskiej‐Curie Institute Onco‐Hematology Warsaw Poland
| | - A. Rambaldi
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - S. Viviani
- Istituto Europeo di Ematologia Hematology Milano Italy
| | - A. Sureda
- Institut Català d'Oncologia Hematology Barcelona Spain
| | - M. André
- Cliniques universitaires Saint‐Luc ‐ UC Louvain Hematology Louvain Belgium
| | - C. Rossi
- CHU Bocage Hematology Dijon France
| | - A. Moccia
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - E. Zucca
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - D. Rossi
- Istituto Oncologico della Svizzera Italiana Hematology Bellinzona Switzerland
| | - A. Filippi
- Policlinico S. Matteo IRCCS Radiation Oncology Pavia Italy
| | - M. Meignan
- Henry Mondor Hospital LYSA Imaging Paris France
| | - S. Chauvie
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| | - J. M. Zaucha
- Medical University of Gdansk Hematology Gdansk Poland
| |
Collapse
|
4
|
Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E. DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.22_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L Ceriani
- Ente Ospedaliero Cantonale Clinic of Nuclear Medicine and PET/CT Center Lugano Switzerland
| | - L Milan
- Ente Ospedaliero Cantonale Clinic of Nuclear Medicine and PET/CT Center Lugano Switzerland
| | - L Cascione
- Università della Svizzera Italiana Institute of Oncology Research Faculty of Biomedical Sciences Bellinzona Switzerland
| | - G Gritti
- Azienda Ospedaliera Papa Giovanni XXIII Hematology Unit Bergamo Italy
| | - F Dalmasso
- Santa Croce e Carle Hospital Medical Physics Unit Cuneo Italy
| | - F Esposito
- Ente Ospedaliero Cantonale Institute of Southern Switzerland Clinic of Medical Oncology Bellinzona Switzerland
| | - Säm Schär
- Swiss Group for Clinical Cancer Research (SAKK) Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center Bern Switzerland
| | - A Bruno
- Azienda Ospedaliera Papa Giovanni XXIII Department of Nuclear Medicine Bergamo Italy
| | - S Dirnhofer
- University Hospital Basel Institute of Medical Genetics and Pathology Basel Switzerland
| | - L Giovanella
- Ente Ospedaliero Cantonale Clinic of Nuclear Medicine and PET/CT Center Lugano Switzerland
| | - S Hayoz
- Swiss Group for Clinical Cancer Research (SAKK) Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center Bern Switzerland
| | - C Mamot
- Cantonal Hospital Aarau Division of Oncology Aarau Switzerland
| | - A Rambaldi
- Azienda Ospedaliera Papa Giovanni XXIII Hematology Unit Bergamo Italy
| | - S Chauvie
- Santa Croce e Carle Hospital Medical Physics Unit Cuneo Italy
| | - E Zucca
- Ente Ospedaliero Cantonale Institute of Southern Switzerland Clinic of Medical Oncology Bellinzona Switzerland
| |
Collapse
|
5
|
Díaz-Santana PJ, Súarez-Santana CM, Fernández A, Rambaldi A, Consoli F, Puig-Lozano R, Sierra E, Los Monteros AED, Arbelo M. Seminoma in an adult striped dolphin Stenella coeruleoalba: tomographic, macroscopical, histological and immunohistochemical study. Dis Aquat Organ 2020; 140:97-101. [PMID: 32701065 DOI: 10.3354/dao03496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Testicular neoplasms have been extensively described and characterized in domestic animals, but reports in wildlife species, including marine mammals, are scarce. This case report describes a testicular seminoma in an adult striped dolphin Stenella coeruleoalba stranded along the coasts of the Canary Islands. Post-mortem computerized tomography (CT) showed a prominent enlargement of the cranial pole of the right testicle, displacing the intestinal loops. Necropsy gross findings confirmed the presence of a testicular mass, bulging at the cut surface, with multiple well-delimitated whitish nodular lesions. Histologically, intratubular and diffuse neoplastic germinative cell proliferation was described. Complementary immunohistochemical assessments for vimentin and CD117 antibodies were negative. To the authors' knowledge, this is the first seminoma described in a S. coeruleoalba. We suggest that post-mortem (PM) pre-necropsy CT in dolphins is a useful tool for anatomic-guided pathology in such cases.
Collapse
Affiliation(s)
- P J Díaz-Santana
- Veterinary Histology and Pathology, Atlantic Center of Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 2019; 30:2015. [PMID: 31539020 PMCID: PMC6938597 DOI: 10.1093/annonc/mdz386] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- S Ciavarella
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - M C Vegliante
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - M Fabbri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - S De Summa
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - F Melle
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - G Motta
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - V De Iuliis
- Post-graduated Medical School of Clinical Pathology, "Gabriele D'Annunzio", University of Chieti, Chieti
| | - G Opinto
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Enjuanes
- Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain
| | - S Rega
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Gulino
- Tumor Immunology Unit, Dipartimento per la Promozione della Salute e Materno Infantile "G. D'Alessandro", University of Palermo, Palermo
| | - C Agostinelli
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - A Scattone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - S Tommasi
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Mangia
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - F Mele
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - G Simone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A F Zito
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - G Ingravallo
- Pathology Section, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", Bari
| | - U Vitolo
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino
| | - A Chiappella
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino
| | - C Tarella
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan
| | - A M Gianni
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan
| | - A Rambaldi
- Department of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo; School of Medicine, University of Milan, Milan, Italy
| | - P L Zinzani
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - B Casadei
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - E Derenzini
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan
| | - G Loseto
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Pileri
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - V Tabanelli
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - S Fiori
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - A Rivas-Delgado
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain
| | - A López-Guillermo
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain
| | - T Venesio
- Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - A Sapino
- Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy; Department of Medical Sciences, University of Torino, Turin, Italy
| | - E Campo
- CIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona; University of Barcelona, Barcelona, Spain
| | - C Tripodo
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Guarini
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - S A Pileri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| |
Collapse
|
7
|
Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 2019; 29:2363-2370. [PMID: 30307529 PMCID: PMC6311951 DOI: 10.1093/annonc/mdy450] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression digitally quantified by NanoString technology on a validation set of 175 formalin-fixed, paraffin-embedded DLBCLs from two randomized trials. Data from an unsupervised clustering analysis were used to build a model of clustering assignment, whose prognostic value was also assessed on an independent cohort of 40 cases. All tissue samples consisted of pretreatment biopsies of advanced-stage DLBCLs treated by comparable R-CHOP/R-CHOP-like regimens. Results In silico analysis demonstrated that higher proportion of myofibroblasts (MFs), dendritic cells, and CD4+ T cells correlated with better outcomes and the expression of genes in our panel is associated with a risk of overall and progression-free survival. In a multivariate Cox model, the microenvironment genes retained high prognostic performance independently of the cell-of-origin (COO), and integration of the two prognosticators (COO + TME) improved survival prediction in both validation set and independent cohort. Moreover, the major contribution of MF-related genes to the panel and Gene Set Enrichment Analysis suggested a strong influence of extracellular matrix determinants in DLBCL biology. Conclusions Our study identified new prognostic categories of DLBCL, providing an easy-to-apply gene panel that powerfully predicts patients’ survival. Moreover, owing to its relationship with specific stromal and immune components, the panel may acquire a predictive relevance in clinical trials exploring new drugs with known impact on TME.
Collapse
Affiliation(s)
- S Ciavarella
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - M C Vegliante
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - M Fabbri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - S De Summa
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - F Melle
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Motta
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - V De Iuliis
- Post-graduated Medical School of Clinical Pathology, "Gabriele D'Annunzio", University of Chieti, Chieti, Italy
| | - G Opinto
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Enjuanes
- Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBERONC, Barcelona, Spain
| | - S Rega
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Gulino
- Tumor Immunology Unit, Dipartimento per la Promozione della Salute e Materno Infantile "G. D'Alessandro", University of Palermo, Palermo, Italy
| | - C Agostinelli
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - A Scattone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - S Tommasi
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Mangia
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - F Mele
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - G Simone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A F Zito
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - G Ingravallo
- Pathology Section, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", Bari, Italy
| | - U Vitolo
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - A Chiappella
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - C Tarella
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan, Italy
| | - A M Gianni
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan, Italy
| | - A Rambaldi
- Department of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy; School of Medicine, University of Milan, Milan, Italy
| | - P L Zinzani
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - B Casadei
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - E Derenzini
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Loseto
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Pileri
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - V Tabanelli
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Fiori
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - A Rivas-Delgado
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain
| | - A López-Guillermo
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain
| | - T Venesio
- Pathology Department, Candiolo Cancer Institute, Turin, Italy
| | - A Sapino
- Pathology Department, Candiolo Cancer Institute, Turin, Italy
| | - E Campo
- CIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - C Tripodo
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Guarini
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - S A Pileri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
| |
Collapse
|
8
|
Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW, Cerana S, Dictar MO, Bonvehi P, Tregnaghi JP, Fein L, Ashley D, Singh M, Hayes T, Playford G, Morrissey O, Thaler J, Kuehr T, Greil R, Pecherstorfer M, Duck L, Van Eygen K, Aoun M, De Prijck B, Franke FA, Barrios CHE, Mendes AVA, Serrano SV, Garcia RF, Moore F, Camargo JFC, Pires LA, Alves RS, Radinov A, Oreshkov K, Minchev V, Hubenova AI, Koynova T, Ivanov I, Rabotilova B, Minchev V, Petrov PA, Chilingirov P, Karanikolov S, Raynov J, Grimard D, McNeil S, Kumar D, Larratt LM, Weiss K, Delage R, Diaz-Mitoma FJ, Cano PO, Couture F, Carvajal P, Yepes A, Torres Ulloa R, Fardella P, Caglevic C, Rojas C, Orellana E, Gonzalez P, Acevedo A, Galvez KM, Gonzalez ME, Franco S, Restrepo JG, Rojas CA, Bonilla C, Florez LE, Ospina AV, Manneh R, Zorica R, Vrdoljak DV, Samarzija M, Petruzelka L, Vydra J, Mayer J, Cibula D, Prausova J, Paulson G, Ontaneda M, Palk K, Vahlberg A, Rooneem R, Galtier F, Postil D, Lucht F, Laine F, Launay O, Laurichesse H, Duval X, Cornely OA, Camerer B, Panse J, Zaiss M, Derigs HG, Menzel H, Verbeek M, Georgoulias V, Mavroudis D, Anagnostopoulos A, Terpos E, Cortes D, Umanzor J, Bejarano S, Galeano RW, Wong RSM, Hui P, Pedrazzoli P, Ruggeri L, Aversa F, Bosi A, Gentile G, Rambaldi A, Contu A, Marei L, Abbadi A, Hayajneh W, Kattan J, Farhat F, Chahine G, Rutkauskiene J, Marfil Rivera LJ, Lopez Chuken YA, Franco Villarreal H, Lopez Hernandez J, Blacklock H, Lopez RI, Alvarez R, Gomez AM, Quintana TS, Moreno Larrea MDC, Zorrilla SJ, Alarcon E, Samanez FCA, Caguioa PB, Tiangco BJ, Mora EM, Betancourt-Garcia RD, Hallman-Navarro D, Feliciano-Lopez LJ, Velez-Cortes HA, Cabanillas F, Ganea DE, Ciuleanu TE, Ghizdavescu DG, Miron L, Cebotaru CL, Cainap CI, Anghel R, Dvorkin MV, Gladkov OA, Fadeeva NV, Kuzmin AA, Lipatov ON, Zbarskaya II, Akhmetzyanov FS, Litvinov IV, Afanasyev BV, Cherenkova M, Lioznov D, Lisukov IA, Smirnova YA, Kolomietz S, Halawani H, Goh YT, Drgona L, Chudej J, Matejkova M, Reckova M, Rapoport BL, Szpak WM, Malan DR, Jonas N, Jung CW, Lee DG, Yoon SS, Lopez Jimenez J, Duran Martinez I, Rodriguez Moreno JF, Solano Vercet C, de la Camara R, Batlle Massana M, Yeh SP, Chen CY, Chou HH, Tsai CM, Chiu CH, Siritanaratkul N, Norasetthada L, Sriuranpong V, Seetalarom K, Akan H, Dane F, Ozcan MA, Ozsan GH, Kalayoglu Besisik SF, Cagatay A, Yalcin S, Peniket A, Mullan SR, Dakhil KM, Sivarajan K, Suh JJG, Sehgal A, Marquez F, Gomez EG, Mullane MR, Skinner WL, Behrens RJ, Trevarthe DR, Mazurczak MA, Lambiase EA, Vidal CA, Anac SY, Rodrigues GA, Baltz B, Boccia R, Wertheim MS, Holladay CS, Zenk D, Fusselman W, Wade III JL, Jaslowsk AJ, Keegan J, Robinson MO, Go RS, Farnen J, Amin B, Jurgens D, Risi GF, Beatty PG, Naqvi T, Parshad S, Hansen VL, Ahmed M, Steen PD, Badarinath S, Dekker A, Scouros MA, Young DE, Graydon Harker W, Kendall SD, Citron ML, Chedid S, Posada JG, Gupta MK, Rafiyath S, Buechler-Price J, Sreenivasappa S, Chay CH, Burke JM, Young SE, Mahmood A, Kugler JW, Gerstner G, Fuloria J, Belman ND, Geller R, Nieva J, Whittenberger BP, Wong BMY, Cescon TP, Abesada-Terk G, Guarino MJ, Zweibach A, Ibrahim EN, Takahashi G, Garrison MA, Mowat RB, Choi BS, Oliff IA, Singh J, Guter KA, Ayrons K, Rowland KM, Noga SJ, Rao SB, Columbie A, Nualart MT, Cecchi GR, Campos LT, Mohebtash M, Flores MR, Rothstein-Rubin R, O'Connor BM, Soori G, Knapp M, Miranda FG, Goodgame BW, Kassem M, Belani R, Sharma S, Ortiz T, Sonneborn HL, Markowitz AB, Wilbur D, Meiri E, Koo VS, Jhangiani HS, Wong L, Sanani S, Lawrence SJ, Jones CM, Murray C, Papageorgiou C, Gurtler JS, Ascensao JL, Seetalarom K, Venigalla ML, D'Andrea M, De Las Casas C, Haile DJ, Qazi FU, Santander JL, Thomas MR, Rao VP, Craig M, Garg RJ, Robles R, Lyons RM, Stegemoller RK, Goel S, Garg S, Lowry P, Lynch C, Lash B, Repka T, Baker J, Goueli BS, Campbell TC, Van Echo DA, Lee YJ, Reyes EA, Senecal FM, Donnelly G, Byeff P, Weiss R, Reid T, Roeland E, Goel A, Prow DM, Brandt DS, Kaplan HG, Payne JE, Boeckh MG, Rosen PJ, Mena RR, Khan R, Betts RF, Sharp SA, Morrison VA, Fitz-Patrick D, Congdon J, Erickson N, Abbasi R, Henderson S, Mehdi A, Wos EJ, Rehmus E, Beltzer L, Tamayo RA, Mahmood T, Reboli AC, Moore A, Brown JM, Cruz J, Quick DP, Potz JL, Kotz KW, Hutchins M, Chowhan NM, Devabhaktuni YD, Braly P, Berenguer RA, Shambaugh SC, O'Rourke TJ, Conkright WA, Winkler CF, Addo FEK, Duic JP, High KP, Kutner ME, Collins R, Carrizosa DR, Perry DJ, Kailath E, Rosen N, Sotolongo R, Shoham S, Chen T. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases 2019; 19:1001-1012. [DOI: 10.1016/s1473-3099(19)30310-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 12/25/2022]
|
9
|
Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia 2019; 33:2974-2978. [PMID: 31363161 PMCID: PMC6884668 DOI: 10.1038/s41375-019-0524-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 05/11/2019] [Accepted: 05/17/2019] [Indexed: 12/15/2022]
Affiliation(s)
- J Mascarenhas
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | | | - J Prchal
- Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - A Yacoub
- University of Kansas Cancer Center, Kansas City, KS, USA
| | - D Berenzon
- Comprehensive Cancer Center, Wake Forest University Medical Center, Wake Forest Health, Winston-Salem, NC, USA
| | - M R Baer
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
| | - E Ritchie
- Weill Cornell Medical College, New York, NY, USA
| | - R T Silver
- Weill Cornell Medical College, New York, NY, USA
| | - C Kessler
- Georgetown University Medical Center, Washington, DC, USA
| | - E Winton
- Winship Cancer Institute Emory University School of Medicine, Atlanta, GA, USA
| | - M C Finazzi
- Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.,Department of Oncology, University of Milan, Milan, Italy
| | - A M Vannucchi
- CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - D Leibowitz
- Oncology Department, Palo Alto Medical Foundation Sutter Health, Sunnyvale, CA, USA
| | - D Rondelli
- Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA
| | - M O Arcasoy
- Duke University School of Medicine, Durham, NC, USA
| | - R Catchatourian
- Oncology Department, John H Stroger Jr. Hospital of Cook County Chicago, Chicago, IL, USA
| | - J Vadakara
- Geisinger Medical Center, Danville, PA, USA
| | - V Rosti
- Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology, and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, 19, viale Golgi, 27100, Pavia, Italy
| | - E Hexner
- University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA
| | - M Kremyanskaya
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - L Sandy
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J Tripodi
- Department of Pathology and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - V Najfeld
- Department of Pathology and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - N Farnoud
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - M E Salama
- Mayo Medical Laboratories, Rochester, MN, USA
| | | | - R Rampal
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - J D Goldberg
- Departments of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, USA
| | - R Mesa
- UT Health San Antonio Cancer Center, San Antonio, TX, USA
| | | | - R Hoffman
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
10
|
Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, Oppi S, Viviani S, Bolis S, Trentin L, Gini G, Battistini R, Chauvie S, Bertolotti L, Pavoni C, Parvis G, Zanotti R, Gavarotti P, Cimminiello M, Schiavotto C, Viero P, Avigdor A, Tarella C, Rambaldi A. CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.105_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Gallamini
- Research & Clinical Innovation; Antoine Lacassagne Cancer Centre; Nice France
| | - A. Rossi
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| | - C. Patti
- Hematology; V. Cervello Hospital; Palermo Italy
| | - M. Picardi
- Hematology; Policlinico Federico II; Naples Italy
| | - A. Romano
- Hematology; Policlinico Vittorio Emanuele Hospital; Catania Italy
| | - M. Cantonetti
- Hematology; Policlinico Hospital Tor Vergata; Rome Italy
| | - S. Oppi
- Hematology; Businco Oncology Hospital; Cagliari Italy
| | - S. Viviani
- Hematology; National Institute of tumors; Milan Italy
| | - S. Bolis
- Hematology; S. Gerardo University Hospital; Monza Italy
| | | | - G. Gini
- Hematology; Ospedali Riuniti Le Torrette; Ancona Italy
| | - R. Battistini
- Hematology; S. Camillo Forlanini Hospital; Rome Italy
| | - S. Chauvie
- Medical Physics; S. Croce Hospital; Cuneo Italy
| | | | - C. Pavoni
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| | - G. Parvis
- Hematology; Mauriziano Hospital; Turin Italy
| | - R. Zanotti
- Hematology; Azienda Ospedaliera Universitaria Integrata; Verona Italy
| | - P. Gavarotti
- Hematology; University Hospital Città della salute; Turin Italy
| | | | | | - P. Viero
- Hematology; Dell'Angelo Hospital; Venice Italy
| | - A. Avigdor
- Hematolog and Bone Marrow Transplantation; Sheba Medical Center; Tel-Aviv Israel
| | - C. Tarella
- Hematology; European Institute of Oncology; Milan Italy
| | - A. Rambaldi
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| |
Collapse
|
11
|
Gallamini A, Schiano de Colella J, Viotti J, Bijou F, Rambaldi A, Perrot A, Patti C, Gastaud L, Sorasio R, Debaigt C, Schiappa R, Chamorey E, Viviani S, Thyss A. BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). Hematol Oncol 2019. [DOI: 10.1002/hon.101_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Gallamini
- Clinical Research and Innovation; A. Lacassagne Cancer Center; Nice France
| | | | - J. Viotti
- Département d'Epidemiologie; de Biostatistiques et des Données de Santé, Centre Antoine Lacassagne; Nice France
| | - F. Bijou
- Oncologie Médicale; Institut Bergonié; Bordeaux France
| | - A. Rambaldi
- Ematologia; Ospedale Papa Giovanni XXII; Bergamo Italy
| | - A. Perrot
- Service Hématologie et Médecine Interne; CHU Nancy-Brabois; Vandoeuvre Les Nancy France
| | - C. Patti
- Ematologia; Ospedali Riuniti Villa Sofia e Cervello; Palermo Italy
| | - L. Gastaud
- Département d'Oncologie Médicale; Centre Antoine Lacassagne; Nice France
| | - R. Sorasio
- Ematologia; Ospedale Sante Croce e Carle; Cuneo Italy
| | - C. Debaigt
- Clinical Research and Innovation; A. Lacassagne Cancer Center; Nice France
| | - R. Schiappa
- Département d'Epidemiologie; de Biostatistiques et des Données de Santé, Centre Antoine Lacassagne; Nice France
| | - E. Chamorey
- Département d'Epidemiologie; de Biostatistiques et des Données de Santé, Centre Antoine Lacassagne; Nice France
| | - S. Viviani
- Dipartimento di Oncologia Medica; Istituto Nazionale Dei Tumori; Milano Italy
| | - A. Thyss
- Département d'Oncologie Médicale; Centre Antoine Lacassagne; Nice France
| |
Collapse
|
12
|
Lopez-Parra M, Bellei M, Rambaldi A, Novelli S, Panizo C, Martelli M, Dhouly I, Bastos M, Gutierrez A, Sancho J, Ramirez M, Moraleda J, Carrillo Cruz E, Jimenez Ubieto A, Jarque I, Vittolo U, de las Heras N, Arranz R, Lopez-Jimenez J, Montalbán C, Pascual M, Corradini P, Bobillo S, Estefania G, Spina M, Rossi G, Manni M, Federico M, Caballero D, Martín A. AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.63_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- M. Lopez-Parra
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| | - M. Bellei
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena; Modena Italy
| | - A. Rambaldi
- Hematology and bone marrow transplant Unit; University of Milan; Milan Italy
| | - S. Novelli
- Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - C. Panizo
- Hematology; Clínica Universidad de Navarra; Pamplona Spain
| | - M. Martelli
- Hematology; Sapienza, University of Rome; Rome Italy
| | - I. Dhouly
- Hematology; Hospital Clinic de Barcelona; Barcelona Spain
| | - M. Bastos
- Hematology; Hospital Gregorio Marañón; Madrid Spain
| | - A. Gutierrez
- Hematology; Hospital Son de Espases; Palma Spain
| | - J. Sancho
- Hematology; Hospital Germans Trias i Pujol/ ICO-IJC; Barcelona Spain
| | - M. Ramirez
- Hematology; Hospital de Jerez de la Frontera; Jerez de la Frontera Spain
| | - J. Moraleda
- Hematology; Hospital Vírgen de la Arrixaca; Murcia Spain
| | | | | | - I. Jarque
- Hematology; Hospital Universitario y Politécnico La Fe; Valencia Spain
| | - U. Vittolo
- Dipartimento di Oncologia e Ematologia; Città della Salute e della Scienza di Torino; Turin Italy
| | - N. de las Heras
- Hematology; Complejo Asistencial Universitario de León; León Spain
| | - R. Arranz
- Hematology; Hospital La Princesa; Madrid Spain
| | | | - C. Montalbán
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - M. Pascual
- Hematology; Hospital Carlos Haya; Málaga Spain
| | | | - S. Bobillo
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | | | - M. Spina
- Division of Medical Oncology; National Cancer Institute; Aviano Italy
| | - G. Rossi
- Hematology; Spedali Civili; Brescia Italy
| | - M. Manni
- Diagnostic; Clinic and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Hematology; Università degli Studi di Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| | - A. Martín
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| |
Collapse
|
13
|
Ceriani L, Pirosa M, Stathis A, Gritti G, Ruberto T, Bruno A, Moccia A, Rambaldi A, Ferrari S, Giovannella L, Hayoz S, Mazzucchelli L, Dirnhofer S, Mamot C, Zucca E. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. Hematol Oncol 2019. [DOI: 10.1002/hon.47_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L. Ceriani
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Pirosa
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Gritti
- Hematology Unit; ASST Papa Giovanni XXIII; Bergamo Italy
| | - T. Ruberto
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Bruno
- Department of Nuclear Medicine; ASST Papa Giovanni XXIII; Bergamo Italy
| | - A. Moccia
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Rambaldi
- Hematology Unit; ASST Papa Giovanni XXIII; Bergamo Italy
| | - S. Ferrari
- Hematology Unit; ASST Papa Giovanni XXIII; Bergamo Italy
| | - L. Giovannella
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - S. Hayoz
- Coordinating Center; SAKK; Bern Switzerland
| | | | - S. Dirnhofer
- Institute of Medical Genetics and Pathology; University Hospital; Basel Switzerland
| | - C. Mamot
- Medical Oncology; Cantonal Hospital; Aarau Switzerland
| | - E. Zucca
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
14
|
Pileri S, Mazzara S, Derenzini E, Melle F, Motta G, Tabanelli V, Vitolo U, Chiappella A, Fabbri M, Agostinelli C, Tarella C, Rambaldi A, Guarini A, Opinto G, Vegliante M, De Summa S, Ciavarella S. INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL. Hematol Oncol 2019. [DOI: 10.1002/hon.98_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S.A. Pileri
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - S. Mazzara
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - E. Derenzini
- Onco-Hematology Unit; European Institute of Oncology, IRCCS; Milan Italy
| | - F. Melle
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - G. Motta
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - V. Tabanelli
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Chiappella
- Department of Hematology; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - M. Fabbri
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - C. Agostinelli
- Department of Experimental; Diagnostic and Specialty Medicine (DIMES), Bologna University School of Medicine; Bologna Italy
| | - C. Tarella
- Onco-Hematology Unit; European Institute of Oncology, IRCCS; Milan Italy
| | - A. Rambaldi
- Department of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo and University of Milan, School of Medicine; Milan Italy
| | - A. Guarini
- Hematology and Cell Therapy Unit; IRCCS-Istituto Tumori 'Giovanni Paolo II'; Bari Italy
| | - G. Opinto
- Hematology and Cell Therapy Unit; IRCCS-Istituto Tumori 'Giovanni Paolo II'; Bari Italy
| | | | - S. De Summa
- Hematology and Cell Therapy Unit; IRCCS-Istituto Tumori 'Giovanni Paolo II'; Bari Italy
| | | |
Collapse
|
15
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
16
|
Baron F, Labopin M, Ruggeri A, Volt F, Mohty M, Blaise D, Chevallier P, Sanz J, Fegueux N, Cornelissen JJ, Rambaldi A, Savani BN, Gluckman E, Nagler A. Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. J Intern Med 2019; 285:446-454. [PMID: 30561052 DOI: 10.1111/joim.12870] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukaemia (sAML). METHODS Inclusion criteria consisted of ≥18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT. RESULTS One hundred forty-six patients met the study inclusion criteria. Status at transplantation was first CR (n = 97), primary refractory sAML (n = 30) or relapsed (n = 19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This includes 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P = 0.008). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P = 0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P = 0.03), respectively. At 2-year overall survival, leukaemia-free survival and graft-versus-host disease (GVHD)-free relapse-free survival were 42% vs. 19% (P < 0.001), 40% vs. 16% (P < 0.001), and 26% vs. 12% (P = 0.002) in first CR patients versus those with advanced disease, respectively. CONCLUSIONS We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR.
Collapse
Affiliation(s)
- F Baron
- Hematology, CHU and GIGA-I3, University of Liege, Liege, Belgium
| | - M Labopin
- AP-HP, Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.,EBMT Paris Office, Hospital Saint Antoine, Paris, France
| | - A Ruggeri
- Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Roma, Italy
| | - F Volt
- Eurocord, Hospital Saint Louis, AP-HP, and IUH University Paris VII, France Monacord, Centre Scientifique de Monaco, Principauté de Monaco, Monaco
| | - M Mohty
- Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Université Pierre & Marie Curie and INSERM UMRs U938, Paris, France
| | - D Blaise
- Transplant and cellular immunotherapy program, Department of Hematology CRCM, Inserm, CNRS, Aix Marseille Univ, Institut Paoli Calmettes, Marseille, France
| | - P Chevallier
- Department of Hematology, CHU of Nantes, Nantes, France
| | - J Sanz
- Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain
| | - N Fegueux
- Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France
| | - J J Cornelissen
- Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | - A Rambaldi
- Department of Oncology and Hematology, University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - B N Savani
- Vanderbilt University Medical Center, Nashville, TN, USA
| | - E Gluckman
- Eurocord, Hospital Saint Louis, AP-HP, and IUH University Paris VII, France Monacord, Centre Scientifique de Monaco, Principauté de Monaco, Monaco
| | - A Nagler
- EBMT Paris Office, Hospital Saint Antoine, Paris, France.,Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
| |
Collapse
|
17
|
Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. J Intern Med 2018; 283:371-379. [PMID: 29214689 DOI: 10.1111/joim.12720] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND Disease recurrence remains the major cause of death in adults with acute myeloid leukaemia (AML) treated using either intensive chemotherapy (IC) or allogenic stem cell transplantation (allo-SCT). AIMS The timely delivery of maintenance drug or cellular therapies represent emerging strategies with the potential to reduce relapse after both treatment modalities, but whilst the determinants of overall relapse risk have been extensively characterized the factors determining the timing of disease recurrence have not been characterized. MATERIALS AND METHODS We have therefore examined, using a series of sequential landmark analyses, relapse kinetics in a cohort of 2028 patients who received an allo-SCT for AML in CR1 and separately 570 patients treated with IC alone. RESULTS In the first 3 months after allo-SCT, the factors associated with an increased risk of relapse included the presence of the FLT3-ITD (P < 0.001), patient age (P = 0.012), time interval from CR1 to transplant (P < 0.001) and donor type (P = 0.03). Relapse from 3 to 6 months was associated with a higher white cell count at diagnosis (P = 0.001), adverse-risk cytogenetics (P < 0.001), presence of FLT3-ITD mutation (P < 0.001) and time interval to achieve first complete remission (P = 0.013). Later relapse was associated with adverse cytogenetics, mutated NPM1, absence of chronic graft-versus-host disease (GVHD) and the use of in vivo T-cell depletion. In patients treated with IC alone, the factors associated with relapse in the first 3 months were adverse-risk cytogenetics (P < 0.001) and FLT3-ITD status (P = 0.001). The factors predicting later relapse were the time interval from diagnosis to CR1 (P = 0.22) and time interval from CR1 to IC (P = 0.012). DISCUSSION AND CONCLUSION Taken together, these data provide novel insights into the biology of disease recurrence after both allo-SCT and IC and have the potential to inform the design of novel maintenance strategies in both clinical settings.
Collapse
Affiliation(s)
- C Craddock
- Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
| | - J Versluis
- Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
| | - M Labopin
- Department of Haematology, Hospital Saint Antoine, Paris, France
| | - G Socie
- Department of Hematology, Hospital Saint-Louis, Sorbonne University, Paris, France
| | - A Huynh
- Department of Haematology, CHU, Toulouse, France
| | - E Deconinck
- Department of Hematology, CHU, Besancon, France
| | - L Volin
- Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland
| | - N Milpied
- Department of Hamatology, CHU, Nantes, France
| | - J H Bourhis
- Department of Medical Oncology, Institute of Cancer, Villejuif, France
| | - A Rambaldi
- Department of Hematology, University of Milan, Milan, Italy
| | | | - D Blaise
- Department of Hematology, Centre of Cancer Research, Marseille, France
| | - M Manz
- Center for Hemato-Oncology, University Hospital Zurich, Zurich, Switzerland
| | - E Vellenga
- Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
| | - M-C Vekemans
- Department of Hematology, Saint-Luc University, Brussels, Belgium
| | - J Maertens
- Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium
| | - J Passweg
- Department of Haematology, University of Basel, Basel, Switzerland
| | - P Vyas
- Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - C Schmid
- Stem Cell Transplantation Unit, Department of Medicine, University of Munich, Munich, Germany
| | - B Löwenberg
- Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
| | - G Ossenkoppele
- Department of Haematology, University Medical Center, Amsterdam, The Netherlands
| | - M Mohty
- Hospital Saint-Antoine, University UPMC, Paris, France
| | - J J Cornelissen
- Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
| | - A Nagler
- Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.,ALWP office of the EBMT Hospital Saint Antoine, Paris, France
| | | |
Collapse
|
18
|
Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol 2018; 28:1547-1553. [PMID: 28368509 DOI: 10.1093/annonc/mdx154] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Indexed: 12/25/2022] Open
Abstract
Background Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, however in Europe it is only approved for patients who are not eligible for HSCT. Patients and methods We conducted a phase II multicenter study to prospectively evaluate the feasibility of HSCT after treatment with AZA in 70 patients with a myelodysplastic syndrome (MDS), 19 with acute myeloid leukemia (AML), and 8 with chronic myelomonocytic leukemia (CMML). After a median of four cycles (range 1-11): 24% of patients achieved complete remission, 14% partial remission, 8% hematologic improvement, 32% had stable and 22% progressive disease. Ten patients discontinued treatment before the planned four cycles, due to an adverse event in nine cases. Results A HSC donor was identified in 73 patients, and HSCT was performed in 54 patients (74% of patients with a donor). Main reasons for turning down HSCT were lack of a donor, an adverse event, or progressive disease (9, 12, and 16 patients, respectively). At a median follow-up of 20.5 months from enrolment, response to AZA was the only independent prognostic factor for survival. Compared to baseline assessment, AZA treatment did not affect patients' comorbidities at HSCT: the HCT-CI remained stable in 62% patients, and worsened or improved in 23% and 15% of patients, respectively. Conclusions Our study shows that HSCT is feasible in the majority of patients with HR-MDS/AML/CMML-2 after AZA treatment. As matched unrelated donor was the most frequent source of donor cells, the time between diagnosis and HSCT needed for donor search could be 'bridged' using azacitidine. These data show that AZA prior to HSCT could be a better option than intensive chemotherapy in higher-risk MDS. The trial has been registered with the EudraCT number 2010-019673-1.
Collapse
Affiliation(s)
- M T Voso
- Division of Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome
| | - G Leone
- Department of Hematology, Università Cattolica del Sacro Cuore, Rome
| | - A Piciocchi
- Department of Statistical Sciences, La Sapienza University, Rome
| | - L Fianchi
- Department of Hematology, Università Cattolica del Sacro Cuore, Rome
| | - S Santarone
- Department of Hematology, Centro Trapianti Midollo Osseo, Pescara
| | - A Candoni
- Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Udine
| | - M Criscuolo
- Department of Hematology, Università Cattolica del Sacro Cuore, Rome
| | - A Masciulli
- Department of Hematology, ASST Papa Giovanni XXIII, Bergamo
| | - E Cerqui
- Department of Hematology, A.O. Spedali Civili, Brescia
| | - A Molteni
- Department of Hematology, Ospedale Niguarda, Milano
| | - C Finelli
- Department of Hematology, Ospedale Sant'Orsola Malpighi, University of Bologna, Bologna
| | - M Parma
- Department of Hematology, HSCT Adult Unit, San Gerardo Hospital, Monza
| | - A Poloni
- Department of Hematology, Azienda Ospedaliera Universitaria - Ospedali Riuniti di Ancona, Ancona
| | - A M Carella
- Department of Hematology, Ospedale Opera Padre Pio, San Giovanni Rotondo
| | - F Spina
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - A Cortelezzi
- Department of Hematology Oncology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milano
| | - F Salvi
- Department of Hematology, "SS Antonio e Biagio" Hospital, Alessandria
| | - E P Alessandrino
- Department of Hematology, Policlinico San Matteo and Pavia University, Pavia, Italy
| | - A Rambaldi
- Department of Hematology, ASST Papa Giovanni XXIII, Bergamo
| | - S Sica
- Department of Hematology, Università Cattolica del Sacro Cuore, Rome
| |
Collapse
|
19
|
Rambaldi A, Cozzi B, Grandis A, Canova M, Mazzoni M, Bombardi C. Distribution of Calretinin Immunoreactivity in the Lateral Nucleus of the Bottlenose Dolphin (Tursiops truncatus
) Amygdala. Anat Rec (Hoboken) 2017; 300:2008-2016. [DOI: 10.1002/ar.23634] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 04/05/2017] [Accepted: 04/06/2017] [Indexed: 01/13/2023]
Affiliation(s)
- A.M. Rambaldi
- Department of Veterinary Medical Sciences (UNI EN ISO 9001:2008); University of Bologna; Bologna Italy
| | - B. Cozzi
- Department of Comparative Biomedicine and Food Science; University of Padova; Padova Italy
| | - A. Grandis
- Department of Veterinary Medical Sciences (UNI EN ISO 9001:2008); University of Bologna; Bologna Italy
| | - M. Canova
- Department of Veterinary Medical Sciences (UNI EN ISO 9001:2008); University of Bologna; Bologna Italy
| | - M. Mazzoni
- Department of Veterinary Medical Sciences (UNI EN ISO 9001:2008); University of Bologna; Bologna Italy
| | - C. Bombardi
- Department of Veterinary Medical Sciences (UNI EN ISO 9001:2008); University of Bologna; Bologna Italy
| |
Collapse
|
20
|
Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia 2017; 32:438-449. [PMID: 28745329 PMCID: PMC5808097 DOI: 10.1038/leu.2017.220] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 06/16/2017] [Accepted: 06/26/2017] [Indexed: 01/13/2023]
Abstract
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by hyperplastic megakaryopoiesis and myelofibrosis. We recently described the upregulation of MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) in PMF CD34+ hematopoietic progenitor cells (HPCs) compared to healthy donor. Here we demonstrated that MAF is also upregulated in PMF compared with the essential thrombocytemia (ET) and polycytemia vera (PV) HPCs. MAF overexpression and knockdown experiments shed some light into the role of MAF in PMF pathogenesis, by demonstrating that MAF favors the megakaryocyte and monocyte/macrophage commitment of HPCs and leads to the increased expression of proinflammatory and profibrotic mediators. Among them, we focused our further studies on SPP1 and LGALS3. We assessed SPP1 and LGALS3 protein levels in 115 PMF, 47 ET and 24 PV patients plasma samples and we found that SPP1 plasma levels are significantly higher in PMF compared with ET and PV patients. Furthermore, in vitro assays demonstrated that SPP1 promotes fibroblasts and mesenchymal stromal cells proliferation and collagen production. Strikingly, clinical correlation analyses uncovered that higher SPP1 plasma levels in PMF patients correlate with a more severe fibrosis degree and a shorter overall survival. Collectively our data unveil that MAF overexpression contributes to PMF pathogenesis by driving the deranged production of the profibrotic mediator SPP1.
Collapse
Affiliation(s)
- S Ruberti
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - E Bianchi
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - P Guglielmelli
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - S Rontauroli
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - G Barbieri
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - L Tavernari
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - T Fanelli
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - R Norfo
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy.,Haematopoietic Stem Cell Biology Laboratory, MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - V Pennucci
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - G Corbizi Fattori
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.,GenOMec, University of Siena, Siena, Italy
| | - C Mannarelli
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.,GenOMec, University of Siena, Siena, Italy
| | - N Bartalucci
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - B Mora
- Division of Hematology, Ospedale ASST Sette Laghi, Universita degli Studi dell'Insubria, Varese, Italy
| | - L Elli
- Division of Hematology, Ospedale ASST Sette Laghi, Universita degli Studi dell'Insubria, Varese, Italy
| | - M A Avanzini
- Department of Pediatric Onco-Hematology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
| | - C Rossi
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - S Salmoiraghi
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - R Zini
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - S Salati
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - Z Prudente
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - V Rosti
- Center for the Study of Myelofibrosis, Foundation IRCCS Policlinico San Matteo, Pavia, Italy
| | - F Passamonti
- Division of Hematology, Ospedale ASST Sette Laghi, Universita degli Studi dell'Insubria, Varese, Italy
| | - A Rambaldi
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - S Ferrari
- Department of Life Sciences, Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy
| | - E Tagliafico
- Department of Life Sciences, Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy
| | - A M Vannucchi
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - R Manfredini
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
21
|
Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect 2017; 23:935-940. [PMID: 28668466 DOI: 10.1016/j.cmi.2017.06.023] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 06/15/2017] [Accepted: 06/17/2017] [Indexed: 12/18/2022]
Abstract
SCOPE Hepatitis B virus (HBV) infection reactivation is associated with high morbidity and mortality in patients with haematologic malignancy and/or haematopoietic stem cell transplantation (HSCT). However, information on this issue is limited. The scope of this position paper is to provide recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in the patients described above. METHODS These recommendations were developed from one meeting of experts attended by different Italian scientific societies as well as from a systematic literature review (of articles published through December 31, 2016) on HBV infection in haematologic patients and in patients who underwent haematopoietic stem cell transplantation published in the same issue of the journal. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess each recommendation's quality. QUESTIONS ADDRESSED These recommendations provide the answers to the following questions: (a) HBV screening and monitoring: Who should be screened before chemotherapy? Which screening tests should be used? Should HBV-DNA detection be used to monitor HBV reactivation before starting antivirals? What is the best timeline to monitor HBV reactivation? (b) Prophylaxis in HBsAg-positive patients: Which antiviral drugs should be used to treat HBsAg-positive patients? How long should antiviral prophylaxis be provided to HBsAg-positive patients? (c) Prophylaxis in patients with resolved HBV infection: Which patients with resolved HBV infection should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (d) HBV infection management strategy in autologous (auto-HSCT) and allogeneic HSCT (allo-HSCT): Which HSCT recipients should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (e) Choice of antiviral drugs in the treatment of HBV reactivation: Should third-generation anti-HBV drugs be preferred to first- or second-generation antiviral drugs in the treatment of HBV reactivation with or without hepatitis flare in haematologic patients? (f) Immunization against HBV in patients with haematologic malignancies and/or patients who underwent HSCT: Should these patients be vaccinated? Which HBV vaccination schedule should be adopted? RECOMMENDATIONS Haematologic patients should be screened for hepatitis B surface antigen (HBsAg) plus anti-hepatitis B core protein (HBc), and HBV DNA before chemotherapy. HBV DNA levels should be monitored monthly in all HBV-positive patients who do not receive prophylaxis. HBsAg-positive haematologic patients and those undergoing HSCT should receive third-generation antiviral therapy as prophylaxis. Anti-HBc-positive lymphoma patients and those receiving HSCT should receive antiviral prophylaxis. All HBV-negative haematologic patients should be vaccinated for HBV. The acquisition of data from well-designed studies is desirable in the near future.
Collapse
Affiliation(s)
- L Sarmati
- Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy.
| | - M Andreoni
- Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy
| | - G Antonelli
- Department of Molecular Medicine, 'La Sapienza' University, Rome, Italy
| | - W Arcese
- Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy
| | - R Bruno
- Department of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
| | - N Coppola
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy
| | - G B Gaeta
- Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, Università della Campania, Naples, Italy
| | - M Galli
- Infectious Diseases Unit, University of Milan, L. Sacco Hospital, Milan, Italy
| | - C Girmenia
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, La Sapienza University, Rome, Italy
| | - M Mikulska
- Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy; Division of Infectious Diseases, IRCCS San Martino University Hospital-IST, Genoa, Italy
| | - F Pane
- Department of Clinical Medicine and Surgery, Hematology, Federico II University, Naples, Italy
| | - C F Perno
- Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy
| | - M Picardi
- Department of Clinical Medicine and Surgery, Hematology, Federico II University, Naples, Italy
| | - M Puoti
- Infectious Diseases Department, Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy
| | - A Rambaldi
- Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - V Svicher
- Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy
| | - G Taliani
- Clinic of Infectious and Tropical Medicine, Policlinico Umberto I, Rome, Italy
| | - G Gentile
- Department of Cellular Biotechnologies and Hematology, 'La Sapienza' University, Rome, Italy
| |
Collapse
|
22
|
Kaplan J, Gordon L, Infante J, Popat R, Rambaldi A, Madan S, Patel M, Gritti G, El-Sharkawi D, Chau I, Radford J, Perez De Oteyza J, Zinzani P, Iyer S, Faucette S, Sheldon-Waniga E, Stumpo K, Shou Y, Carpio C, Bosch F. TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_60] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Kaplan
- Department of Medicine; Northwestern University; Chicago USA
| | - L. Gordon
- Robert H Lurie Comprehensive Cancer Center; Northwestern University Feinberg School of Medicine; Chicago USA
| | - J. Infante
- Drug Development Unit; Sarah Cannon Research Institute/Tennessee Oncology; Nashville USA
| | - R. Popat
- NIHR Clinical Research Facility; UCLH; London UK
| | - A. Rambaldi
- Dipartimento di Oncologia ed Emato-Oncologia / Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano / Ospedale Papa Giovanni XXII; Bergamo Italy
| | - S. Madan
- Dipartimento di Oncologia ed Emato-Oncologia/Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano/Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - M.R. Patel
- Hematology-Oncology; Florida Cancer Specialists/Sarah Cannon Research Institute; Sarasota USA
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - D. El-Sharkawi
- Haematology; NIHR UCLH Clinical Research Facility; London UK
| | - I. Chau
- Department of Medicine; Royal Marsden Hospital; Surrey UK
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | | | - P. Zinzani
- Hematology, Institute of Hematology “Seragnoli”; University of Bologna; Bologna Italy
| | - S. Iyer
- Advanced Therapeutics, Institute of Academic Medicine; Houston Methodist Cancer Center; Houston USA
| | - S. Faucette
- Clinical Pharmacology; Takeda Pharmaceuticals International Co.; Cambridge USA
| | | | - K. Stumpo
- Oncology Clinical Research; Takeda Pharmaceuticals; Cambridge USA
| | - Y. Shou
- Oncology Clinical Research; Takeda Pharmaceuticals International Co.; Cambridge USA
| | - C. Carpio
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - F. Bosch
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| |
Collapse
|
23
|
Lussana F, Di Ianni M, Rambaldi A. Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2017; 52:1225-1232. [DOI: 10.1038/bmt.2017.30] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Revised: 10/11/2016] [Accepted: 10/14/2016] [Indexed: 02/06/2023]
|
24
|
Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 2016; 31:970-973. [DOI: 10.1038/leu.2016.351] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
25
|
Saraceni F, Bruno B, Lemoli RM, Meloni G, Arcese W, Falda M, Ciceri F, Alessandrino EP, Specchia G, Scimè R, Raimondi R, Bacigalupo A, Bosi A, Onida F, Rambaldi A, Bonifazi F, Olivieri A. Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. Bone Marrow Transplant 2016; 52:163-166. [PMID: 27668760 DOI: 10.1038/bmt.2016.233] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F Saraceni
- Hematology and Bone Marrow Transplantation, Polytechnic University of Marche-Ospedali Riuniti, Ancona, Italy
| | - B Bruno
- National Registry GITMO & Data Managing, Ospedale San Martino, Genova, Italy
| | - R M Lemoli
- Hematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S. Martino-IST, Genova, Italy
| | - G Meloni
- Hematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University of Rome, Rome, Italy
| | - W Arcese
- Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy
| | - M Falda
- Hematology 2 Unit, San Giovanni Battista Hospital and University, Turin, Italy
| | - F Ciceri
- Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy
| | - E P Alessandrino
- Department of Hematology, University of Pavia, Policlinico S Matteo-IRCCS, Pavia, Italy
| | - G Specchia
- Hematology Department, University of Bari, Bari, Italy
| | - R Scimè
- Department of Hematology and Bone Marrow Transplant Unit Ospedale Cervello, Palermo, Italy
| | - R Raimondi
- Department of Hematology, S Bortolo Hospital, Vicenza, Italy
| | - A Bacigalupo
- Institute of Haematology, Università Cattolica Sacro Cuore, Roma, Italy
| | - A Bosi
- Haematology Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
| | - F Onida
- Hematology - BMT Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - A Rambaldi
- Hematology and BMT Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - F Bonifazi
- Hematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S. Martino-IST, Genova, Italy
| | - A Olivieri
- Hematology and Bone Marrow Transplantation, Polytechnic University of Marche-Ospedali Riuniti, Ancona, Italy
| |
Collapse
|
26
|
Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A. Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. Bone Marrow Transplant 2016; 52:238-244. [PMID: 27643865 DOI: 10.1038/bmt.2016.239] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Revised: 07/22/2016] [Accepted: 07/27/2016] [Indexed: 12/27/2022]
Abstract
This study evaluated the safety and efficacy of thiotepa-based regimens before allogeneic stem cell transplantation in 310 adult patients with AML. Disease status at the time of transplantation was CR1 in 50%, CR2+ in 23.5% and advanced disease in 26.5%. Transplantation was performed from haploidentical (35%), matched sibling (27%), unrelated (20%) or cord blood (18%) donors. As for safety: mucositis occurred in 46.8% of the patients and the cumulative incidence (CI) of sinusoidal obstruction syndrome was 4.0%. With a median follow-up of 37 months, the CI of acute GvHD grade>II was 26.5%, whereas CI of chronic GvHD was 28.1% at 3 years. CI for non-relapse mortality at 3 years was 38.4%, 49.7% and 45.4% for patients in CR1, CR2+ and advanced disease, respectively (P=0.10). Relapse incidence at 3 years was 20.2, 30.7 and 40.6% in these three respective groups (P=0.002). CI for 3-year leukemia-free survival and overall survival were 41.4% and 45.6% (CR1), 19.6% and 27.7% (CR2+), and 13.9% and 13.6% (advanced disease), respectively (P<10-4 for both). Our data suggest that thiotepa-based conditioning therapy in AML is feasible, effective and safe, as investigated for sinusoidal obstruction syndrome and mucositis.
Collapse
Affiliation(s)
- S Eder
- EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
| | - M Labopin
- EBMT Office Paris, Hôpital Saint-Antoine, Paris, France
| | - J Finke
- Department of Medicine-Hematology, Oncology, University of Freiburg, Freiburg, Germany
| | - D Bunjes
- Klinik fuer Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany
| | - A Olivieri
- Department of Hematology, Azienda Ospedali Riuniti di Ancona, Ancona-Torrete, Italy
| | - S Santarone
- Department of Hematology, Ospedale Civile, Pescara, Italy
| | - A Rambaldi
- USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - L Kanz
- Abteilung II, Universität Tübingen, Tübingen, Germany
| | - G Messina
- Centro Trapianti Midollo Osseo, Azienda Ospedaliera 'BMM', Reggio Calabria, Italy
| | - M Mohty
- EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
| | - A Nagler
- EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.,Chaim Sheba Medical Center, Tel-Hashomer, Israel
| |
Collapse
|
27
|
Rambaldi A, Grandis A, Mazzoni M, Tagliavia C, Clavenzani P, Cozzi B, Bombardi C. Calcitonin Gene-Related Peptide (CGRP) expression in the spinal cord and spinal ganglia of the Bottlenose Dolphin ( Tursiops truncatus ). Ann Anat 2016. [DOI: 10.1016/j.aanat.2016.04.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, Crawley C, Rambaldi A, Russell N, Anders W, Blaise D, Yakoub-Agha I, Ganser A, Castagna L, Volin L, Cahn JY, Montoto S, Dreger P. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†. Ann Oncol 2016; 27:1088-1094. [PMID: 26961149 DOI: 10.1093/annonc/mdw124] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Revised: 02/17/2016] [Accepted: 02/22/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Patients with follicular lymphoma (FL) relapsing after an autologous transplant (autoSCT) may be treated with a variety of therapies, including a reduced intensity allogeneic transplant (RICalloSCT). We conducted a retrospective analysis of a large cohort of patients undergoing RICalloSCT for FL in this setting. PATIENTS AND METHODS A total of 183 patients, median age 45 years (range 21-69), had undergone an autoSCT at a median of 30 months before the RICalloSCT. Before the RICalloSCT, they had received a median of four lines (range 3-10) of therapy and 81% of patients had chemosensitive disease and 16% had chemoresistant disease. Grafts were donated from sibling (47%) or unrelated donors (53%). RESULTS With a median follow-up of 59 months, the non-relapse mortality (NRM) was 27% at 2 years. The median remission duration post-autoSCT and RICalloSCT was 14 and 43 months, respectively. The 5-year relapse/progression rate, progression-free survival and overall survival were 16%, 48% and 51%, respectively, and were associated with age and disease status at RICalloSCT. CONCLUSION These data suggest that an RICalloSCT is an effective salvage strategy in patients with FL recurring after a prior autoSCT and might overcome the poor prognostic impact of early relapse after autoSCT.
Collapse
Affiliation(s)
- S P Robinson
- BMT Unit, University Hospital Bristol NHS Foundation Trust, Bristol, UK; Lymphoma Working Party EBMT, Paris, France.
| | | | - H Finel
- Lymphoma Working Party EBMT, Paris, France
| | - H Schouten
- Department of Haematology, University Hospital, Maastricht, The Netherlands
| | - G Ehninger
- Department of Haematology, Universitaetsklinikum, Dresden, Germany
| | - J Maertens
- Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium
| | - C Crawley
- Department of Haematology, Addenbrookes Hospital, Cambridge, UK
| | - A Rambaldi
- Haematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - N Russell
- Department of Haematology, City Hospital, Nottingham, UK
| | - W Anders
- Department of Haematology, University Hospital, Umea, Sweden
| | - D Blaise
- Department of Haematology, Institut Paoli Calmettes, Marseille
| | - I Yakoub-Agha
- Department of Haematology, Hôpital Claude Huriez, Lille, France
| | - A Ganser
- Department of Haematology, Medical School, Hannover, Germany
| | - L Castagna
- Department of Haematology, Istituto Clinico Humanitas, Milano, Italy
| | - L Volin
- HUH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - J-Y Cahn
- Haematology, Clinique Universitaire d'Hématologie CHU Grenoble UMR 38043, Grenoble Cedex 09, France
| | - S Montoto
- Lymphoma Working Party EBMT, Paris, France; Department of Haematology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - P Dreger
- Lymphoma Working Party EBMT, Paris, France; Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
29
|
Giaccherini C, Verzeroli C, Marchetti M, Gamba S, Piras F, Russo L, Tessarolo S, Vignoli A, Finazzi G, Rambaldi A, Falanga A. PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). Thromb Res 2016; 140 Suppl 1:S185-6. [PMID: 27161713 DOI: 10.1016/s0049-3848(16)30159-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are two MPNs characterized by a "clonal" overproduction of one or more blood cell lines, hypercoagulability, and an increased incidence of thrombosis. ROTEM is a point of care global coagulation assay performed in whole blood, able to evaluate platelets and fibrinogen contributions to the clotting process. Until now few studies evaluated the thromboelastometry profile of MPN patients. AIM This study assess the feasibility of using ROTEM to characterize the prothrombotic state of MPN patients and to evaluate whether the thromboelastometry profile varies according to mutational status and/or treatment, and is influenced by hemocromocytometric parameters. MATERIALS AND METHODS Venous blood samples were collected from 39 ET and 23PV patients upon informed consent. Analysis was performed using INTEM and EXTEM reagents, to evaluate the intrinsic and extrinsic pathway, respectively. Maximum clot firmness (MCF, [mm]), which reflects the maximum tensile strength of the thrombus, clotting formation time (CFT [sec]), namely the time that clot takes to increase from 2 to 20mm above baseline, and clotting time (CT [sec]), the time to clot initiation, were recorded. Nineteen healthy subjects acted as a control group. RESULTS ROTEM analysis showed a hypercoagulable profile in MPN patients, who had shorter CFT and higher MCF compared to controls, both with EXTEM and INTEM reagents; no differences were observed in CT parameters. Platelet count was significantly higher in patients compared to controls (p<0.01). In patients, a strong statistically significant (p<0.01) correlation was found between platelet count, and MCF [r=0.650 (ET), r=0.601 (PV)] or CFT [r=-0.641 (ET), r=-0.558 (PV)]. Multivariate analysis, according to blood cell counts, showed that only platelet count was independently associated to ROTEM results. To correct for platelet differences, a ratio between MCF and the respective platelet value (rMCF) was created. Interestingly, rMCF was significantly lower in patients compared to controls (p<0.01), suggesting a weaker clot formation potential of patients' samples. Furthermore, rMCF was lower in ET compared to PV (p<0.05), and in calreticulin-positive subjects (p<0.05), while was higher in patients under cytoreductive therapy (Hydroxyurea) (p=ns). CONCLUSIONS This study confirms, by the ROTEM evaluation, the occurrence of a hypercoagulable state in ET and PV patients. In addition, the ROTEM parameters are significantly influenced by the platelet count. Finally, MCF values corrected for platelet count reveal a lower platelet reactivity in MPN patients, confirming the hypothesis that platelet function is exhausted upon clotting activation. ACKNOWLEDGEMENT Project funded by "AIRC-IG2013" grant Nr. 14505 from the "Italian Association for Cancer Research" (A.I.R.C.).
Collapse
Affiliation(s)
- C Giaccherini
- Division of Immunohematology and Transfusion Medicine
| | - C Verzeroli
- Division of Immunohematology and Transfusion Medicine
| | - M Marchetti
- Division of Immunohematology and Transfusion Medicine
| | - S Gamba
- Division of Immunohematology and Transfusion Medicine
| | - F Piras
- Division of Immunohematology and Transfusion Medicine
| | - L Russo
- Division of Immunohematology and Transfusion Medicine
| | - S Tessarolo
- Division of Immunohematology and Transfusion Medicine
| | - A Vignoli
- Division of Immunohematology and Transfusion Medicine
| | - G Finazzi
- Division of Hematology; Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- Division of Hematology; Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - A Falanga
- Division of Immunohematology and Transfusion Medicine
| |
Collapse
|
30
|
Vignoli A, Tessarolo S, Marchetti M, Gamba S, Piras F, Finazzi G, van der Meijden P, Swieringa F, ten Cate H, Heemskerk J, Rambaldi A, Falanga A. PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. Thromb Res 2016; 140 Suppl 1:S183. [DOI: 10.1016/s0049-3848(16)30152-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 2015; 5:e369. [PMID: 26617062 PMCID: PMC4670947 DOI: 10.1038/bcj.2015.94] [Citation(s) in RCA: 160] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- T Barbui
- Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.,Division of Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - A M Vannucchi
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - V Buxhofer-Ausch
- Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
| | - V De Stefano
- Institute of Hematology, Catholic University, Rome, Italy
| | - S Betti
- Institute of Hematology, Catholic University, Rome, Italy
| | - A Rambaldi
- Division of Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - E Rumi
- Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy
| | - M Ruggeri
- Division of Hematology, S. Bortolo Hospital, Vicenza, Italy
| | - F Rodeghiero
- Division of Hematology, S. Bortolo Hospital, Vicenza, Italy
| | - M L Randi
- Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - I Bertozzi
- Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - H Gisslinger
- Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
| | - G Finazzi
- Division of Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - A Carobbio
- Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - J Thiele
- Institute for Pathology, University of Cologne, Cologne, Germany
| | - F Passamonti
- University Hospital Ospedale di Circolo and Fondazione Macchi, Division of Hematology, Varese, Italy
| | - C Falcone
- Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - A Tefferi
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
32
|
Curreri R, Bonacina R, Mariani U, Caprioli C, Stefanoni P, Rambaldi A. Progressione del plasmocitoma solitario dell’osso a livello mandibolare in mieloma multiplo. Dental Cadmos 2015. [DOI: 10.1016/s0011-8524(15)30083-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
33
|
Mian M, Marcheselli L, Rossi A, Visco C, Chiappella A, Volpetti S, Zaja F, Mondello P, Fiegl M, Billio A, Federico M, Luminari S, Rambaldi A, Cortelazzo S. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. Ann Oncol 2014; 25:2398-2404. [PMID: 25274614 DOI: 10.1093/annonc/mdu462] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND In the rituximab era, the conventional International Prognostic index (IPI) lost at least in part its predictive power, while the National Comprehensive Cancer Network-IPI (NCCN-IPI) seems to be a new and valid prognosticator. However, it has not yet been evaluated in patients with localized disease and it has not been compared with the modified IPI (mIPI) of the pre-rituximab era. In order to evaluate the different prognosticators and to assess the importance of rituximab and radiotherapy (RT), we carried out the so far largest retrospective analysis of patients with localized diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS We retrospectively assessed clinical and therapeutical data of 1405 patients treated in from 1987 to 2012 in 10 cancer centers in Italy and 1 in Austria. RESULTS All patients underwent an anthracycline containing polychemotherapy and 254 additional rituximab. The median follow-up was 5.7 years (range 0.1-23 years). The 5-year overall survival (OS) was 75%, being significantly superior in those who underwent additional rituximab, while RT consolidation did not improve the outcome of those who received immunochemotherapy. Patients with extranodal disease benefited from the addition of rituximab, while RT did not improve OS of the immunochemotherapy subgroup. In the pre-rituximab era, the mIPI showed a better performance than the others. In rituximab-treated patients, the NCCN-IPI had the highest discriminant value and the 5-years OS varied significantly (P < 0.001) between the three risk groups and was 98% in low-risk patients, 82% in those with a low-intermediate risk and 57% among high-intermediate and high-risk cases. CONCLUSIONS The NCCN-IPI is so far the best prognosticator for patients with localized DLBCL who underwent R-CHOP(-like). The addition of rituximab is indispensable regardless of the risk category and site of involvement, while the addition of RT should be reserved to those cases who are ineligible to rituximab.
Collapse
Affiliation(s)
- M Mian
- Division of Hematology, Hospital of Bolzano, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Austria.
| | - L Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena
| | - A Rossi
- USC Hematology, A.O. Papa Giovanni XXIII, Bergamo
| | - C Visco
- Department of Hematology, Ospedale San Bortolo, Vicenza
| | - A Chiappella
- Division of Hematology 2, Azienda Ospedaliera Città Della Salute e Della Scienza, Turin
| | - S Volpetti
- Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero-Universitaria Udine, Udine
| | - F Zaja
- Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero-Universitaria Udine, Udine
| | - P Mondello
- Department of Medical Oncology, University of Messina, Messina
| | - M Fiegl
- Department of Hematology and Oncology, University Hospital Innsbruck, Austria
| | - A Billio
- Division of Hematology, Hospital of Bolzano, Bolzano, Italy
| | - M Federico
- Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena
| | - S Luminari
- Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena
| | - A Rambaldi
- USC Hematology, A.O. Papa Giovanni XXIII, Bergamo
| | - S Cortelazzo
- Department of Medical Oncology and Hematology, Humanitas Cancer Center, Bergamo, Italy
| |
Collapse
|
34
|
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, Scattolin AM, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J 2014; 4:e225. [PMID: 25014772 PMCID: PMC4219445 DOI: 10.1038/bcj.2014.48] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Affiliation(s)
- R Bassan
- 1] UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy [2] USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - O Spinelli
- USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - E Oldani
- USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - T Intermesoli
- USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Tosi
- USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - B Peruta
- USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - E Borlenghi
- Divisione di Ematologia, Spedali Civili, Brescia, Italy
| | - E M Pogliani
- Clinica Ematologica, Ospedale San Gerardo, Monza, Italy
| | - E Di Bona
- UOC Ematologia, Ospedale S. Bortolo, Vicenza, Italy
| | - V Cassibba
- Divisione di Ematologia, Ospedale Civile, Bolzano, Italy
| | - A M Scattolin
- UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy
| | - C Romani
- UO Ematologia, Ospedale Oncologico di Riferimento Regionale, Cagliari, Italy
| | - F Ciceri
- UO Ematologia, Istituto Scientifico H.S. Raffaele, Milano, Italy
| | - A Cortelezzi
- UO Ematologia I, IRCCS Ca' Granda Ospedale Maggiore Policlinico and Università degli Studi, Milano, Italy
| | - G Gianfaldoni
- Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy
| | - D Mattei
- SC Ematologia, ASO S. Croce e Carle, Cuneo, Italy
| | - E Audisio
- Ematologia 2, Ospedale San Giovanni Battista/Università, Torino, Italy
| | - A Rambaldi
- USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
35
|
Rambaldi A, Biagi E, Bonini C, Biondi A, Introna M. Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014; 29:1-10. [PMID: 24919807 DOI: 10.1038/leu.2014.189] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2014] [Revised: 05/15/2014] [Accepted: 05/27/2014] [Indexed: 12/19/2022]
Abstract
When treatment fails, the clinical outcome of acute leukemia patients is usually very poor, particularly when failure occurs after transplantation. A second allogeneic stem cell transplant could be envisaged as an effective and feasible salvage option in younger patients having a late relapse and an available donor. Unmanipulated or minimally manipulated donor T cells may also be effective in a minority of patients but the main limit remains the induction of severe graft-versus-host disease. This clinical complication has brought about a huge research effort that led to the development of leukemia-specific T-cell therapy aiming at the direct recognition of leukemia-specific rather than minor histocompatibility antigens. Despite a great scientific interest, the clinical feasibility of such an approach has proven to be quite problematic. To overcome this limitation, more research has moved toward the choice of targeting commonly expressed hematopoietic specific antigens by the genetic modification of unselected T cells. The best example of this is represented by the anti-CD19 chimeric antigen receptor (CD19.CAR) T cells. As a possible alternative to the genetic manipulation of unselected T cells, specific T-cell subpopulations with in vivo favorable homing and long-term survival properties have been genetically modified by CAR molecules. Finally, the use of naturally cytotoxic effector cells such as natural killer and cytokine-induced killer cells has been proposed in several clinical trials. The clinical development of these latter cells could also be further expanded by additional genetic modifications using the CAR technology.
Collapse
Affiliation(s)
- A Rambaldi
- Hematology and Bone Marrow Transplant Unit and Center of Cell Therapy 'G. Lanzani', Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - E Biagi
- Department of Pediatrics, M Tettamanti Research Center, Laboratory of Cell therapy 'S. Verri' University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - C Bonini
- Experimental Hematology Unit, San Raffaele Scientific Institute, Milano, Italy
| | - A Biondi
- Department of Pediatrics, M Tettamanti Research Center, Laboratory of Cell therapy 'S. Verri' University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - M Introna
- Hematology and Bone Marrow Transplant Unit and Center of Cell Therapy 'G. Lanzani', Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
36
|
Magni M, Nicola MD, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant 2014; 49:485-91. [DOI: 10.1038/bmt.2013.214] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Revised: 11/19/2013] [Accepted: 11/19/2013] [Indexed: 11/09/2022]
|
37
|
Parolini M, Mecucci C, Matteucci C, Giussani U, Intermesoli T, Tosi M, Rambaldi A, Bassan R. Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient. Blood Cancer J 2014; 4:e176. [PMID: 24442205 PMCID: PMC3913941 DOI: 10.1038/bcj.2013.72] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- M Parolini
- U.S.C. Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - C Mecucci
- Ematologia e Immunologia Clinica, Dipartimento di Medicina Clinica e Sperimentale, Università di Perugia, Perugia, Italy
| | - C Matteucci
- Ematologia e Immunologia Clinica, Dipartimento di Medicina Clinica e Sperimentale, Università di Perugia, Perugia, Italy
| | - U Giussani
- Laboratorio di Genetica Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - T Intermesoli
- U.S.C. Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Tosi
- U.S.C. Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- U.S.C. Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - R Bassan
- U.S.C. Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
38
|
Martini V, Schiavone P, Bonacina R, Mariani U, Rambaldi A. NK leukemia: a rare case of oral manifestations representing the initial sign. Ann Stomatol (Roma) 2013; 4:28. [PMID: 24353795 PMCID: PMC3860219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- V Martini
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - P Schiavone
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - R Bonacina
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - U Mariani
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
39
|
Bonacina R, Martini V, Schiavone P, Mariani U, Rambaldi A. The importance of differential diagnosis between Bronj and hematologic diseases. Ann Stomatol (Roma) 2013; 4:27-28. [PMID: 24353793 PMCID: PMC3860233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- R Bonacina
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - V Martini
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - P Schiavone
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - U Mariani
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
40
|
Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F, Yakoub-Agha I, Ribera JM, Mannone L, Sierra J, Mohty M, Solano C, Nabhan S, Arcese W, Gluckman E, Labopin M, Rocha V. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2013; 28:779-86. [PMID: 24005245 DOI: 10.1038/leu.2013.259] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2013] [Revised: 08/08/2013] [Accepted: 08/14/2013] [Indexed: 01/13/2023]
Abstract
We report outcomes after single (s) and double (d) umbilical cord blood transplantation (UCBT) after myeloablative conditioning (MAC) regimen for 239 patients transplanted for acute leukemia in first complete remission (CR1). All sUCBT patients received a total nucleated cell dose >2.5 × 10(7)/kg. Conditioning regimen for sUCBT was total body irradiation (TBI)12 Gy- or busulfan (BU)-based ± fludarabine (Flu) (n=68, group 1), thiotepa+BU+Flu (TBF) (n=88, group 2), and for dUCBT it was TBI12 Gy+cyclophosphamide ± Flu (n=83, group 3). dUCBT recipients were younger, received higher cell dose and less frequently antithymocyte globulin. In multivariate analysis, we found similar neutrophil recovery among the three groups; however, acute graft-versus-host disease II-IV was higher in dUCBT compared with others. Non-relapse mortality and relapse incidence were not statistically different among the three groups. Leukemia-free survival was 30% for sUCBT using TBI- or BU-based MAC compared with 48% for sUCBT TBF and 48% for dUCBT (P=0.02 and P=0.03, respectively), and it was not statistically different between sUCBT with TBF and dUCBT. In conclusion, use of sUCBT with adequate cell dose (>2.5 × 10(7)/kg) and a specific conditioning regimen in the MAC setting results in similar outcomes as dUCBT. The choice of TBF conditioning regimen for sUCBT may improve results, and whether this regimen may be effective in dUCBT should be further analyzed.
Collapse
Affiliation(s)
- A Ruggeri
- 1] Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France [2] Rome Transplant Network, University Tor Vergata, Rome, Italy
| | - G Sanz
- Hospital Universitario La Fe, Valencia, Spain
| | | | - J Sanz
- Hospital Universitario La Fe, Valencia, Spain
| | - A Rambaldi
- Ospedali Riuniti di Bergamo, Bergamo, Italy
| | - F Volt
- Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France
| | | | - J M Ribera
- ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain
| | | | - J Sierra
- Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - M Mohty
- Hospital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06, UMR-S 938, CEREST-TC EBMT, Paris, France
| | - C Solano
- Hospital Clínico Universitario, Valencia, Spain
| | - S Nabhan
- Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France
| | - W Arcese
- Rome Transplant Network, University Tor Vergata, Rome, Italy
| | - E Gluckman
- Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France
| | - M Labopin
- Hospital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06, UMR-S 938, CEREST-TC EBMT, Paris, France
| | - V Rocha
- 1] Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France [2] Churchill Hospital, Oxford University Hospitals, Oxford, UK
| | | |
Collapse
|
41
|
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27:1874-81. [PMID: 23739289 PMCID: PMC3768558 DOI: 10.1038/leu.2013.163] [Citation(s) in RCA: 454] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Accepted: 05/17/2013] [Indexed: 01/07/2023]
Abstract
Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis were more frequent in women and arterial thrombosis and abnormal karyotype in men. Considering patients from the center with the most mature follow-up information (n=337 with 44% of patients followed to death), median survival (14.1 years) was significantly worse than that of the age- and sex-matched US population (P<0.001). In multivariable analysis, survival for the entire study cohort (n=1545) was adversely affected by older age, leukocytosis, venous thrombosis and abnormal karyotype; a prognostic model that included the first three parameters delineated risk groups with median survivals of 10.9-27.8 years (hazard ratio (HR), 10.7; 95% confidence interval (CI): 7.7-15.0). Pruritus was identified as a favorable risk factor for survival. Cumulative hazard of leukemic transformation, with death as a competing risk, was 2.3% at 10 years and 5.5% at 15 years; risk factors included older age, abnormal karyotype and leukocytes ≥15 × 10(9)/l. Leukemic transformation was associated with treatment exposure to pipobroman or P32/chlorambucil. We found no association between leukemic transformation and hydroxyurea or busulfan use.
Collapse
Affiliation(s)
- A Tefferi
- Division of Hematology, Department of
Medicine, Clinic, Rochester, MN, USA
| | - E Rumi
- Department of Hematology, University of
Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
| | - G Finazzi
- Ospedali Riuniti di Bergamo,
Bergamo, Italy
| | | | - A M Vannucchi
- Department of Hematology, University of
Florence, Florence, Italy
| | | | - M L Randi
- Department of Hematology, University of
Padua, Padua, Italy
| | - R Vaidya
- Division of Hematology, Department of
Medicine, Clinic, Rochester, MN, USA
| | - M Cazzola
- Department of Hematology, University of
Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Rambaldi
- Ospedali Riuniti di Bergamo,
Bergamo, Italy
| | | | - L Pieri
- Department of Hematology, University of
Florence, Florence, Italy
| | | | - I Bertozzi
- Department of Hematology, University of
Padua, Padua, Italy
| | - N H Sulai
- Division of Hematology, Department of
Medicine, Clinic, Rochester, MN, USA
| | - I Casetti
- Department of Hematology, University of
Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Carobbio
- Ospedali Riuniti di Bergamo,
Bergamo, Italy
| | | | - D R Larson
- Division of Hematology, Department of
Medicine, Clinic, Rochester, MN, USA
| | - L Müllauer
- Medical University of Vienna,
Vienna, Austria
| | - A Pardanani
- Division of Hematology, Department of
Medicine, Clinic, Rochester, MN, USA
| | - J Thiele
- Department of Pathology, University of
Cologne, Cologne, Germany
| | | | - T Barbui
- Ospedali Riuniti di Bergamo,
Bergamo, Italy
| |
Collapse
|
42
|
Mian M, Capello D, Ventre MB, Grazio D, Svaldi M, Rossi A, Tsang R, Gospodarowicz MK, Oldani E, Federico M, Luminari S, Marcheselli L, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Gutierrez-Garcia G, Busetto M, Visco C, Fiegl M, Rossi D, Gaidano G, Cavalli F, Zucca E, Rambaldi A, Cortelazzo S. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). Ann Hematol 2013; 93:221-231. [PMID: 23959436 DOI: 10.1007/s00277-013-1856-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2013] [Accepted: 07/18/2013] [Indexed: 11/30/2022]
Abstract
It is known that extranodal head and neck diffuse large B cell lymphomas (eHN-DLBCL) can affect various anatomical structures what is not well-known, however, is whether they differ in terms of clinical presentation and outcome. Clinical data of the multi-institutional series, the largest of its kind as yet, has been analysed with the aim of answering these open questions and providing long-term follow-up information. Data from 488 patients affected by stage I/II eHN-DLBCL was collected: 300 of the Waldeyer's Ring (WR), 38 of the parotid and salivary glands (PSG), 48 of the thyroid gland (TG), 53 of the nasal cavity and paranasal sinuses (NPS), 24 of the palate and oral cavity (POC) and 25 with more than one involved site. Different eHN-DLBCL arising have distinct characteristics at presentation. The intermediate high risk-modified IPI was 67 % in TG, 44 % in WR, 38 % in PSG and POC and 20 % in MS. The worst 5-year survival rate had TG-DLBCL (61 %) due to the 61 % of patients with a mIPI >1. The addition of radiotherapy (cRT) to remitters did not translate into a survival advantage (5-year disease-free survival of 67 % in the cRT group vs. 70 % in the other). Three of four central nervous system recurrences occurred in NPS-DLBCL. Survival of HN-DLBCL was inferior to nodal DLBCL. This study showed that eHN-DLBCL remitters have an inferior survival when compared to nodal DLBCL, and that the addition of cRT does not provide a survival advantage. Since the standard of care nowadays is chemo-immunotherapy, survival of these patients might have been improved.
Collapse
Affiliation(s)
- M Mian
- Division of Hematology, Azienda Ospedaliera S. Maurizio, Bolzano/Bozen, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY, Pohlreich D, Le Gouill S, Gilleece M, Milpied N, Attal M, Biron P, Maury S, Rambaldi A, Maertens J, Capria S, Colombat P, Montoto S, Sureda A. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48:1409-14. [PMID: 23771004 DOI: 10.1038/bmt.2013.83] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2013] [Revised: 04/26/2013] [Accepted: 05/01/2013] [Indexed: 01/04/2023]
Abstract
Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first transplant in this setting. We conducted a retrospective comparison of 726 patients who underwent an auto-SCT and 149 who underwent a RIST as a first transplant procedure for relapsed FL as reported to the Lymphoma Working Party of the European Bone Marrow Transplant. The non-relapse mortality (NRM) was significantly worse for patients undergoing a RIST (relative risk (RR) 4.0, P<0.001). The 1-year NRM was 15% for those undergoing a RIST compared with 3% for those undergoing an auto-SCT. Disease relapse or progression were significantly worse for those receiving an auto-SCT (RR 3.1, P<0.001). Patients undergoing a RIST had a 5-year relapse rate of 20% compared with 47% for those undergoing an auto-SCT. The PFS at 5 years was 57% for patients receiving a RIST compared with 48% for those receiving an auto-SCT. There was no significant difference in OS between the two groups. RIST is associated with a higher NRM and lower relapse rate in patients with relapsed FL.
Collapse
Affiliation(s)
- S P Robinson
- BMT Unit, Bristol Children's Hospital, Bristol, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Bassan R, Scattolin AM, Maino E, Imbergamo S, Spinelli O, Oldani E, Intermesoli T, Rambaldi A. Monoclonal antibody therapy of adult acute lymphoblastic leukemia: progress and challenge for new clinical trials. Drugs Cell Ther Hematol 2013. [DOI: 10.4081/dcth.2013.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
45
|
Bassan R, Scattolin AM, Maino E, Imbergamo S, Spinelli O, Oldani E, Intermesoli T, Rambaldi A. Monoclonal antibody therapy of adult acute lymphoblastic leukemia: progress and challenge for new clinical trials. Drugs Cell Ther Hematol 2013. [DOI: 10.4081/dcth.2013.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
46
|
Signori A, Crocchiolo R, Oneto R, Sacchi N, Sormani MP, Fagioli F, Rambaldi A, Ciceri F, Bacigalupo A. Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant 2012; 47:1474-8. [PMID: 22465976 DOI: 10.1038/bmt.2012.58] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Chronic GVHD (cGVHD) has been associated with reduced risk of relapse after allo-SCT for onco-hematological disease due to a graft-vs-malignancy effect. Here we retrospectively analyzed a series of 802 adult patients transplanted from unrelated donors and found that cGVHD was associated with significantly lower relapse and that the limited form was associated with a survival advantage: hazard ratio for OS=0.63 (0.46-0.87); P=0.004; this was due to combination of relapse reduction and similar non-relapse mortality with respect to patients without cGVHD. Importantly, the graft-vs-malignancy effect observed here did not differ when PBSC or BM were used as stem cell source, thus suggesting that the protective effect of limited cGVHD is similar after PBSC- or BM-based transplantation. These findings could have practical implications and suggest no qualitative difference between cGVHD occurring after transplantation performed with different stem cell sources.
Collapse
Affiliation(s)
- A Signori
- Department of Health Sciences (DISSAL), Section of Biostatistic, University of Genoa, Genova, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Marchetti M, Russo L, Tartari C, Woodhams B, Di Bona E, Rambaldi A, Lo Coco F, Falanga A. New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA. Thromb Res 2012. [DOI: 10.1016/s0049-3848(12)70044-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
48
|
Rondelli D, Goldberg J, Marchioli R, Isola L, Shore T, Prchal J, Bacigalupo A, Rambaldi A, Klisovic R, Gupta V, Andreasson B, Demakos E, Price L, Scarano M, Wetzler M, Vannucchi A, Najfeld V, Barosi G, Silverman L, Hoffman R. Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.039] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
49
|
Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2011; 26:716-9. [PMID: 21926959 DOI: 10.1038/leu.2011.258] [Citation(s) in RCA: 122] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In an international study of 1104 patients with essential thrombocythemia (ET), a histological review according to the 2008 World Health Organization (WHO) criteria confirmed ET in 891 patients (WHO-ET, 81%), and revised the diagnosis to prefibrotic primary myelofibrosis (PMF) in 180 patients (PMF, 16%). Major bleeding during follow-up occurred in 55 (6%) WHO-ET and 21 (12%) PMF patients (P = 0.009), at a rate of 0.79 and 1.39% patients per year, respectively, (P = 0.039). In a multivariable analysis, predictors of bleeding included diagnosis of PMF (P = 0.05; hazard ratio (HR) 1.74), leukocytosis (P = 0.04; HR 1.74), previous hemorrhage (P = 0.025; HR 2.35) and aspirin therapy (P=0.001; HR 3.16). The analysis restricted to patients with WHO-ET confirmed previous hemorrhage (P = 0.043; HR 1.92) and aspirin (P=0.027; HR 2.24) as independent risk factors. The current study reveals that major bleeding associated with thrombocytosis might be relatively specific to PMF, as opposed to WHO-defined ET. Furthermore, it shows that low-dose aspirin exacerbates these hemorrhagic events of PMF. In contrast, thrombocytosis per se was not a risk factor for bleeding; however, low-dose aspirin had a synergistic hemorrhagic effect unmasking the bleeding tendency of patients with extreme thrombocytosis. These observations carry significant therapeutic implications in these two WHO entities.
Collapse
Affiliation(s)
- G Finazzi
- Division of Hematology, Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2011; 26:520-6. [PMID: 21904377 DOI: 10.1038/leu.2011.240] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Rescue chemotherapy or autologous stem cell transplantation (autoSCT) gives disappointing results in relapsed peripheral T-cell lymphomas (PTCLs). We have retrospectively evaluated the long-term outcome of 52 patients receiving allogeneic SCT for relapsed disease. Histologies were PTCL-not-otherwise specified (n=23), anaplastic large-cell lymphoma (n=11), angioimmunoblastic T-cell lymphomas (n=9) and rare subtypes (n=9). Patients were allografted from related siblings (n=33, 64%) or alternative donors (n=13 (25%) from unrelated and 6 (11%) from haploidentical family donors), following reduced-intensity conditioning (RIC) regimens including thiotepa, fludarabine and cyclophosphamide. Most of the patients had chemosensitive disease (n=39, 75%) and 27 (52%) failed a previous autoSCT. At a median follow-up of 67 months, 27 of 52 patients were found to be alive (52%) and 25 (48%) were dead (n=19 disease progression, n=6 non-relapse mortality (NRM)). The cumulative incidence (CI) of NRM was 12% at 5 years. Extensive chronic graft-versus-host disease increased the risk of NRM (33% versus 8%, P=0.04). The CI of relapse was 49% at 5 years, influenced by disease status at the time of allografting (P=0.0009) and treatment lines (P=0.007). Five-year overall survival and progression-free survival (PFS) were 50% (95% CI, 36 - 63%) and 40% (95% CI, 27 - 53%), respectively. The current PFS was 44% (95% CI, 30-57%). In all, 8 out of 12 patients (66%) who received donor-lymphocytes infusions for disease progression had a response. At multivariable analysis, refractory disease and age over 45 years were independent adverse prognostic factors. RIC allogeneic SCT is an effective salvage treatment with a better outcome for younger patients with chemosensitive disease.
Collapse
Affiliation(s)
- A Dodero
- Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|